News Valeant's Siliq price undercuts rivals to offset black box w... Siliq will be cheaper than rivals from Novartis and Eli Lilly.
News Novartis and Allergan to combine drugs in NASH Swiss pharma also aims for new CAR-T therapy indication.
News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
News Kite keeps pressure on Novartis with CAR-T filing Kite completes filing a day after rival Novartis.
News Novartis edges ahead in CAR-T race Novartis has filed its CAR-T cell therapy with the FDA, giving it an edge over Kite Pharma and its rival treatment.
Views & Analysis Why Novartis and Verily should abandon their smart lens idea Technical officer hinted that the firm has hit obstacles to its ambitious projects.
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
